News
MBC BioLabs Alum, Loyal, Makes Headlines with their Pioneering Longevity Drugs for Dogs
Aiming to bridge the longevity gap between breeds, Loyal, a pet longevity company, is on the verge of a veterinary breakthrough
Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
LabCentral, BioLabs, and MBC BioLabs announced an agreement to boost early-stage innovations through access to Evotec’s leading shared end-to-end R&D platform.
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis
Ionic Liquids - Changing the Game One Indication at a Time
This Startup Just Raised $26 Million To Develop Safer Gene Editing Tools
Amber Bio Raises 26M to Develop Safer Gene-Editing Tools
UCSF researchers’ startup aims to stop allergies — starting with babies’ guts
UCSF spinout targets allergic diseases by resetting babies' guts
Forbes 30 under 30 List
Felix Wong Cofounder, Integrated Biosciences Cambridge, Massachusetts Read original [...]
Venture Capitalist ROBUST Announces Investment in Symbiome
Venture Capitalist ROBUST Announces Investment in Sustainable Life Sciences Brand Symbiome
Industry Winner of the 2022 Grant Program
The winner of the industry category was Dr. Julia Durack from Symbiome in the USA!
Podcast: Building the Bay Area Life Sciences Startup Ecosystems
Lab to Startup Podcast with Regis Kelly and Doug Crawford
Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study
Siolta initiates dosing in newborn subjects in a groundbreaking trial of STMC-103H
Switch Bioworks Raises $4.3M to Feed a Growing World Sustainably
Next-generation biofertilizer startup sets out to tackle climate change with synthetic biology and microbes.
MBC BioLabs Announces New Partnership with Benchling
Benchling’s R&D Cloud makes it easier to capture and access the data you need, collaborate as a team, and accelerate decision making.
MBC BioLabs is Excited to Welcome Shimadzu as its Newest Partner
Shimadzu's Nexera Prep HPLC System is available at MBC BioLabs @ 930 Brittan.
Dorian Therapeutics
The Discovery to Youthfulness and Regeneration
Dren Bio Announces Research Collaboration and License Agreement with Pfizer
Dren Bio received $25 million upfront payment as part of overall deal for selected oncology targets that includes over $1 billion in potential cash payments plus potential future product-based sales royalties
Eisai and MBC BioLabs Announce Winner of Golden Ticket Competition
Eisai and MBC BioLabs Announce Winner of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery
MBC BioLabs welcomes Eisai Innovation, Inc. as our newest partner
MBC BioLabs is thrilled to announce our latest partner is Eisai Innovation, Inc. (EII), an affiliate of Eisai Co., Ltd. the fully integrated pharmaceutical company based in Tokyo, Japan.
Revel Pharmaceuticals revels in new Agilent program
Revel has tapped the Agilent Instrument Subscriptions Program to gain access to a mass spectrometer, critical in the startup’s work to combat the damages of aging.
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Soteria, a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, announces $42 Million Series A Financing.
Alessa Therapeutics Announces First Australian Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer
Alessa Therapeutics announces the enrollment of the first patient in their clinical study in Australia. The Biolen-PC study will treat up to 20 patients in Australia and New Zealand.
Fujifilm Joins MBC Biolabs as Sponsor to Foster Innovation in Biotech
MBC BioLabs is excited to announce a strategic partnership with Fujifilm Open Innovation Hub to support biotech collaboration and innovation in our startup ecosystem.
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
ONO Entered Sponsorship Agreements with MBC BioLabs and LabCentral
This sponsorship will allow ONO to early access the most updated information of the biotech startups and others residing in LabCentral and MBC BioLabs facilities.